eligibility_summary
Adults ≥18 with resected CRC and MRD (ctDNA+, no radiologic disease), ECOG 0–1, >3 mo, adequate organs, LVEF>50%, O2>92%, use contraception (WOCBP: negative test), agree to sampling and stay within 2 h of site for 4 wks. Exclude: active disease, pregnancy/lactation, recent therapy/RT/live vaccine, prior gene‑modified T/NK, immunodeficiency/high‑dose steroids, malignancy, autoimmune, ILD, active infection (HIV/HBV/HCV/TB), allogeneic transplant, major CV/QTc>480, bleeding risk (DVT/PE on AC OK).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions and mechanisms: 1) TROP2-CAR-NK cells—allogeneic cord blood–derived natural killer cells engineered with a TROP2-specific CAR and transduced with IL-15 (cell therapy). Mechanism: targeted NK cytotoxicity against TROP2+ CRC cells, IL-15 enhances NK survival, proliferation, and persistence. 2) Cetuximab—anti-EGFR IgG1 monoclonal antibody (biologic). Mechanism: blocks EGFR signaling and induces ADCC via NK cell FcγRIIIa (CD16), designed to synergize with CAR-NK activity. 3) Lymphodepleting chemotherapy: fludarabine (purine analog) and cyclophosphamide (alkylating agent) to reduce host lymphocytes and improve CAR-NK engraftment. 4) Rimiducid (AP1903, small-molecule dimerizer), listed for potential activation of an inducible safety switch to eliminate infused cells if needed. Targeted cells/pathways: TROP2 on tumor cells, EGFR pathway, NK activation/persistence (IL-15), ADCC via CD16.